GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NKTR · Mar 31, 2026

NEKTAR THERAPEUTICS. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001193125-26-212596General Corporate

Capex intensity20thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.17% · OPTIONAL · VALID

Operating cash generation30thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-407.86% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

3.83% · CORE · NOT_ENOUGH_HISTORY

Operating margin10thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.operating_margin

-359.58% · CORE · VALID

R&D intensity100thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

328.51% · OPTIONAL · VALID

SBC intensity60thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

30.89% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History8 statesHistory building

Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/6 normalizedLevel 3 Jun 30, 20250/6 normalizedLevel 3 Sep 30, 20255/6 normalizedLevel 3 Dec 31, 20255/7 normalizedLevel 3 Mar 31, 20265/6 normalizedLevel 3 Jun 30, 20265/6 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 0.31%
Current: 0.17%
Delta: -0.14%

Cash Generation Decreased

Previous: -377.52%
Current: -407.86%
Delta: -30.34%

Growth Increased

Previous: -43.89%
Current: 3.83%
Delta: 47.72%

Profitability Decreased

Previous: -253.66%
Current: -359.58%
Delta: -105.92%

R And D Intensity Increased

Previous: 212.43%
Current: 328.51%
Delta: 116.08%

Sbc Intensity Increased

Previous: 22.90%
Current: 30.89%
Delta: 7.99%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · NEKTAR THERAPEUTICS →Transitioned To · NKTR Fundamental State →Transitioned To · NKTR CAPEX_INTENSITY_DECREASED →Transitioned To · NKTR CASH_GENERATION_DECREASED →Transitioned To · NKTR GROWTH_INCREASED →Transitioned To · NKTR PROFITABILITY_DECREASED →Transitioned To · NKTR R_AND_D_INTENSITY_INCREASED →Transitioned To · NKTR SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.